Anebulo Pharmaceuticals Inc

ANEB | $2.85 -5.0% -7.14% 4.9K

(0.0% 1d) (23.3% 1m) (5.7% 1y) (0.0% 2d) (0.0% 3d) (1.7% 7d) (-55.91% volume)
Earnings Calendar: 2023-09-08
Market Cap: $ 73,054,668
https://www.anebulo.com
Sec Filling | Patents | 2 employees

Anebulo is a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid overdose and substance addiction. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within one hour of administration. Clinical trials completed to date have shown that ANEB-001 is rapidly absorbed, well tolerated and leads to weight loss, an effect that is consistent with central cannabinoid receptor type 1 antagonism.

add to watch list Paper trade email alert is off

Press-releases

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates
Published: 2024-02-13 (Crawled : 23:00) - biospace.com/
ANEB | $2.85 -5.0% -7.14% 4.9K

Manufacturing

| 20.33% | O: 6.5% H: 0.38% C: -1.53%
year pharmaceuticals financial results

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates
Published: 2023-09-20 (Crawled : 21:00) - biospace.com/
ANEB | $2.85 -5.0% -7.14% 4.9K

Manufacturing

| -15.19% | O: 0.29% H: 2.86% C: -0.57%
year pharmaceuticals financial results

Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension
Published: 2023-08-21 (Crawled : 13:20) - biospace.com/
ANEB | $2.85 -5.0% -7.14% 4.9K

Manufacturing

| 5.71% | O: 7.5% H: 12.62% C: 2.66%
aneb-001 fda positive extension

Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates
Published: 2023-05-11 (Crawled : 12:00) - prnewswire.com
ANEB | $2.85 -5.0% -7.14% 4.9K

Manufacturing

| 28.7% | O: -1.74% H: 2.88% C: 2.88%
pharmaceuticals financial results

Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication
Published: 2023-03-28 (Crawled : 13:00) - biospace.com/
ANEB | $2.85 -5.0% -7.14% 4.9K

Manufacturing

| 2.42% | O: -4.67% H: 19.78% C: 5.63%
aneb-001 positive treatment pharmaceuticals potential

Anebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions
Published: 2023-03-08 (Crawled : 14:00) - biospace.com/
ANEB | $2.85 -5.0% -7.14% 4.9K

Manufacturing